Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A)
- Conditions
- Colorectal CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma
- Interventions
- Drug: Rescue medicationDrug: Supportive care measures
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06428409
- Locations
- 🇺🇸
UCLA ( Site 0317), Los Angeles, California, United States
🇺🇸University of Colorado Anschutz Medical Campus ( Site 0299), Aurora, Colorado, United States
🇺🇸UCHealth Cherry Creek Medical Center ( Site 0326), Denver, Colorado, United States
Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
- Conditions
- Rectal Neoplasms
- Interventions
- Radiation: Short-course radiotherapyRadiation: Long-course chemoradiation
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Pei-Rong Ding
- Target Recruit Count
- 66
- Registration Number
- NCT06417476
- Locations
- 🇨🇳
651 Dongfeng Road East, Guangzhou, Guangdong, China
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
- Conditions
- Efficacy and Safety
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Target Recruit Count
- 120
- Registration Number
- NCT06383078
Photoradiation with Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaStage II Pancreatic Cancer AJCC V8Stage III Pancreatic Cancer AJCC V8Stage IV Pancreatic Cancer AJCC V8Unresectable Pancreatic Adenocarcinoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Endoscopic UltrasoundProcedure: Lymph Node BiopsyProcedure: Magnetic Resonance ImagingDrug: Photodynamic TherapyProcedure: Positron Emission TomographyOther: Questionnaire Administration
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT06381154
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 117
- Registration Number
- NCT06370754
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT06341296
- Locations
- 🇨🇳
West China Hospital，Sichuan University, Sichuan, Sichuan, Chengdu, China
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Procedure: 166Holmium TARE
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 46
- Registration Number
- NCT06332079
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- Conditions
- HER2-positive Gastric CancerColorectal CancerHER2 AmplificationHER2-positive Breast CancerHER2 Positive Solid Tumors
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 275
- Registration Number
- NCT06328738
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Renato Dulbecco, Catanzaro, Italy
🇺🇸BRCR Medical Center Inc., Plantation, Florida, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
- Conditions
- Gastric Cancer
- Interventions
- Procedure: Diagnostic laparoscopyCombination Product: dPIPAC ( The description of the standard diagnostic laparoscopy procedure and the session of PIPAC (dPIPAC)).
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Nizhny Novgorod Regional Clinical Oncology Center
- Target Recruit Count
- 106
- Registration Number
- NCT06313801
- Locations
- 🇷🇺
Research Institute of Clinical Oncology "Nizhny Novgorod Regional Clinical Oncological Dispensary", Nizhny Novgorod, Russian Federation
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
- Conditions
- Colorectal CancerLiver Metastases
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 156
- Registration Number
- NCT06280495
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.